CADMUS - Ustekinumab in adolescent subjects with plaque psoriasis

• Research type

  Research Study

• Full title

  A Phase 3 Multicentre, Randomised, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Adolescent Subjects with Moderate to Severe Plaque-type Psoriasis

• IRAS ID

  87025

• Contact name

  Anthony Bewley

• Sponsor organisation

  Janssen Biologics BV

• Eudract number

  2009-014368-20

• Clinicaltrials.gov Identifier

  NCT01090427

• Research summary

  The purpose of this study is to evaluate the efficacy and safety of 2 subcutaneous dosing tiers of ustekinumab in the treatment of adolescent subjects = 12 to < 18 years of age with moderate to severe chronic plaque psoriasis.

• REC name

  East Midlands - Derby Research Ethics Committee

• REC reference

  11/EM/0305

• Date of REC Opinion

  12 Oct 2011

• REC opinion

  Further Information Favourable Opinion